[{"id":"68ed3b37-b467-4c04-902f-70c0e053d74f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02945579","created_at":"2021-01-18T14:27:45.395Z","updated_at":"2025-02-25T12:26:33.859Z","phase":"","brief_title":"Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy","source_id_and_acronym":"NCT02945579","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PGR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/20/2017","start_date":" 01/20/2017","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-02-24"},{"id":"9563a22f-1431-499b-ba51-cc38d3b74ea7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04345913","created_at":"2021-01-18T21:01:42.609Z","updated_at":"2025-02-25T13:40:07.851Z","phase":"Phase 1/2","brief_title":"Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT04345913","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PIK3CA • PGR • PTEN","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • PIK3CA mutation","tags":["ER • PIK3CA • PGR • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-21"},{"id":"11ed08db-6adc-4dff-97ee-d51d291166de","acronym":"TRACERX-TNBC","url":"https://clinicaltrials.gov/study/NCT03077776","created_at":"2021-01-18T15:09:42.996Z","updated_at":"2025-02-25T13:52:16.877Z","phase":"","brief_title":"Tracking Triple-negative Breast Cancer Evolution Through Therapy","source_id_and_acronym":"NCT03077776 - TRACERX-TNBC","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 149","initiation":"Initiation: 04/14/2017","start_date":" 04/14/2017","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-20"},{"id":"5bdc28e5-7ca8-447b-ae67-6e292adebde6","acronym":"TRIFOUR","url":"https://clinicaltrials.gov/study/NCT05181462","created_at":"2022-01-06T22:53:40.626Z","updated_at":"2025-02-25T15:12:31.656Z","phase":"Phase 1/2","brief_title":"Nadunolimab in Combination with Gemcitabine Plus Carboplatin in Patients with Advanced Triple Negative Breast Cancer.","source_id_and_acronym":"NCT05181462 - TRIFOUR","lead_sponsor":"Cantargia AB","biomarkers":" HER-2 • PD-L1 • ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 negative • HER-2 negative + HR negative • HER-2 negative + HR negative + BRCA mutation","tags":["HER-2 • PD-L1 • ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 negative + HR negative • HER-2 negative + HR negative + BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • nadunolimab (CAN04)"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 01/11/2022","start_date":" 01/11/2022","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-02-13"},{"id":"87a9c1fe-92c6-4692-b3ba-4b7c76aefe9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02993068","created_at":"2021-01-18T14:43:23.226Z","updated_at":"2025-02-25T15:17:22.718Z","phase":"","brief_title":"Stand Up to Cancer: MAGENTA (Making Genetic Testing Accessible)","source_id_and_acronym":"NCT02993068","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRIP1 • RAD51C • RAD51D • BARD1","pipe":" | ","alterations":" PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["ER • PGR • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRIP1 • RAD51C • RAD51D • BARD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"],"overall_status":"Suspended","enrollment":" Enrollment 5200","initiation":"Initiation: 04/18/2017","start_date":" 04/18/2017","primary_txt":" Primary completion: 04/18/2026","primary_completion_date":" 04/18/2026","study_txt":" Completion: 04/18/2026","study_completion_date":" 04/18/2026","last_update_posted":"2025-02-12"},{"id":"a5c52f3d-d931-4d6c-a0fc-d7a329637aae","acronym":"ADAPT-TN-III","url":"https://clinicaltrials.gov/study/NCT06081244","created_at":"2023-10-14T01:13:01.938Z","updated_at":"2025-02-25T15:20:56.304Z","phase":"Phase 2","brief_title":"NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)","source_id_and_acronym":"NCT06081244 - ADAPT-TN-III","lead_sponsor":"West German Study Group","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 348","initiation":"Initiation: 10/10/2024","start_date":" 10/10/2024","primary_txt":" Primary completion: 09/01/2029","primary_completion_date":" 09/01/2029","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2025-02-12"},{"id":"e94eda48-02c6-40bc-8f38-bdeb553754b5","acronym":"CASE6119","url":"https://clinicaltrials.gov/study/NCT04674306","created_at":"2021-01-19T20:45:27.933Z","updated_at":"2025-02-25T15:18:56.819Z","phase":"Phase 1","brief_title":"Adjuvant Therapy with an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer","source_id_and_acronym":"NCT04674306 - CASE6119","lead_sponsor":"George T. Budd","biomarkers":" HER-2 • ER • PGR • BRCA1 • PRL","pipe":" | ","alterations":" HER-2 negative • PALB2 mutation • ER negative","tags":["HER-2 • ER • PGR • BRCA1 • PRL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PALB2 mutation • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alpha-lactalbumin vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-12"},{"id":"e26650cf-8309-4e3f-ba36-361dadb2b1b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02595905","created_at":"2021-01-17T17:31:58.977Z","updated_at":"2025-02-25T16:36:40.508Z","phase":"Phase 2","brief_title":"Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases","source_id_and_acronym":"NCT02595905","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 negative • BRCA mutation","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • veliparib (ABT-888)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 333","initiation":"Initiation: 09/15/2016","start_date":" 09/15/2016","primary_txt":" Primary completion: 03/15/2025","primary_completion_date":" 03/15/2025","study_txt":" Completion: 03/15/2025","study_completion_date":" 03/15/2025","last_update_posted":"2025-02-06"},{"id":"70895122-f43e-478e-b06c-44c96910d6ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04265872","created_at":"2021-04-20T09:53:17.764Z","updated_at":"2025-02-25T16:44:48.890Z","phase":"Phase 1","brief_title":"Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC","source_id_and_acronym":"NCT04265872","lead_sponsor":"Baylor Research Institute","biomarkers":" ER • HRD","pipe":" | ","alterations":" HRD • ER negative","tags":["ER • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • bortezomib"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/15/2020","start_date":" 10/15/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-05"},{"id":"5351b2fd-adc5-41e4-92bd-076122f48c07","acronym":"BRI-ROL-001","url":"https://clinicaltrials.gov/study/NCT03328026","created_at":"2021-01-18T16:26:04.427Z","updated_at":"2025-02-25T16:52:02.280Z","phase":"Phase 1/2","brief_title":"Combination Study of SV-BR-1-GM With Retifanlimab","source_id_and_acronym":"NCT03328026 - BRI-ROL-001","lead_sponsor":"BriaCell Therapeutics Corporation","biomarkers":" ER • PIK3CA • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PGR positive","tags":["ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Zynyz (retifanlimab-dlwr) • epacadostat (INCB024360) • Bria-IMT (SV-BR-1-GM) • Intron A (interferon α-2b) • cyclophosphamide intravenous"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 36","initiation":"Initiation: 03/16/2018","start_date":" 03/16/2018","primary_txt":" Primary completion: 11/03/2025","primary_completion_date":" 11/03/2025","study_txt":" Completion: 11/30/2028","study_completion_date":" 11/30/2028","last_update_posted":"2025-02-04"},{"id":"f03fd2c7-19d1-413f-b17f-ce55b722407c","acronym":"DIRECT","url":"https://clinicaltrials.gov/study/NCT05710328","created_at":"2023-02-02T14:59:59.682Z","updated_at":"2025-02-25T17:38:28.900Z","phase":"Phase 2","brief_title":"Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial","source_id_and_acronym":"NCT05710328 - DIRECT","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative"],"overall_status":"Recruiting","enrollment":" Enrollment 235","initiation":"Initiation: 05/10/2023","start_date":" 05/10/2023","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-01-29"},{"id":"5ab5758f-ded0-479b-83dd-b16b495d0f1a","acronym":"FASCINATE-N","url":"https://clinicaltrials.gov/study/NCT05582499","created_at":"2022-10-17T13:56:00.115Z","updated_at":"2025-02-25T12:29:07.250Z","phase":"Phase 2","brief_title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","source_id_and_acronym":"NCT05582499 - FASCINATE-N","lead_sponsor":"Fudan University","biomarkers":" HER-2 • PGR • CD8 • FOXC1","pipe":"","alterations":" ","tags":["HER-2 • PGR • CD8 • FOXC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • AiRuiLi (adebrelimab) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 716","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-12-27"},{"id":"3554ca16-61bd-4047-833c-b83d03ee0735","acronym":"","url":"https://clinicaltrials.gov/study/NCT06038539","created_at":"2023-09-15T18:09:54.550Z","updated_at":"2025-02-25T13:55:34.751Z","phase":"Phase 3","brief_title":"Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer","source_id_and_acronym":"NCT06038539","lead_sponsor":"Biocon Biologics UK Ltd","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression • ER negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • docetaxel • Perjeta (pertuzumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 382","initiation":"Initiation: 01/31/2025","start_date":" 01/31/2025","primary_txt":" Primary completion: 03/15/2026","primary_completion_date":" 03/15/2026","study_txt":" Completion: 11/15/2026","study_completion_date":" 11/15/2026","last_update_posted":"2024-12-17"},{"id":"9dd1dfec-0aa4-4556-89c3-d62638f6b981","acronym":"","url":"https://clinicaltrials.gov/study/NCT03761914","created_at":"2021-01-18T18:29:09.264Z","updated_at":"2025-02-25T16:08:40.101Z","phase":"Phase 1/2","brief_title":"Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers","source_id_and_acronym":"NCT03761914","lead_sponsor":"Sellas Life Sciences Group","biomarkers":" HER-2 • KRAS • PGR • WT1 • BRCA • MUC16","pipe":" | ","alterations":" HER-2 negative • KRAS wild-type • RAS wild-type • BRCA mutation","tags":["HER-2 • KRAS • PGR • WT1 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • KRAS wild-type • RAS wild-type • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • oxaliplatin • irinotecan • Zeltherva (galinpepimut-S) • hydroxyurea • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 09/30/2019","start_date":" 09/30/2019","primary_txt":" Primary completion: 07/05/2022","primary_completion_date":" 07/05/2022","study_txt":" Completion: 10/27/2022","study_completion_date":" 10/27/2022","last_update_posted":"2024-11-19"},{"id":"70b5ad20-490d-47a2-823e-d4e8dc4746f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01817452","created_at":"2021-01-17T17:34:12.030Z","updated_at":"2025-02-25T14:00:09.311Z","phase":"Phase 2","brief_title":"A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol","source_id_and_acronym":"NCT01817452","lead_sponsor":"West German Study Group","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 03/01/2014","start_date":" 03/01/2014","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-11-13"},{"id":"a6261b4d-283f-45db-9b03-c83871bfbd02","acronym":"","url":"https://clinicaltrials.gov/study/NCT02957968","created_at":"2021-01-18T14:31:51.880Z","updated_at":"2025-02-25T16:05:24.919Z","phase":"Phase 2","brief_title":"Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca","source_id_and_acronym":"NCT02957968","lead_sponsor":"Virginia Commonwealth University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative • HER-2 negative + HR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HER-2 negative + HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • doxorubicin hydrochloride • azacitidine • albumin-bound paclitaxel • cyclophosphamide • decitabine • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 01/24/2017","start_date":" 01/24/2017","primary_txt":" Primary completion: 08/04/2022","primary_completion_date":" 08/04/2022","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-11-11"},{"id":"d51630cc-a526-4c45-ba50-82d026376318","acronym":"U31402-A-J101","url":"https://clinicaltrials.gov/study/NCT02980341","created_at":"2021-01-17T17:33:44.191Z","updated_at":"2025-02-25T16:05:30.233Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT02980341 - U31402-A-J101","lead_sponsor":"Daiichi Sankyo Co., Ltd.","biomarkers":" HER-2 • ERBB3","pipe":" | ","alterations":" HR positive • HER-2 negative • HER-2 expression • ERBB3 positive","tags":["HER-2 • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HER-2 expression • ERBB3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Completed","enrollment":" Enrollment 182","initiation":"Initiation: 11/28/2016","start_date":" 11/28/2016","primary_txt":" Primary completion: 08/16/2021","primary_completion_date":" 08/16/2021","study_txt":" Completion: 09/07/2023","study_completion_date":" 09/07/2023","last_update_posted":"2024-10-30"},{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"3f4801d6-52e8-46ea-a4ce-c058e7891e0e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02187991","created_at":"2021-01-18T10:12:40.272Z","updated_at":"2025-02-25T14:57:00.891Z","phase":"Phase 2","brief_title":"Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer","source_id_and_acronym":"NCT02187991","lead_sponsor":"US Oncology Research","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 169","initiation":"Initiation: 02/12/2015","start_date":" 02/12/2015","primary_txt":" Primary completion: 04/11/2024","primary_completion_date":" 04/11/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-10-09"},{"id":"600fe2c1-8174-4610-9b08-169ca63b195f","acronym":"DESTINY-Breast05","url":"https://clinicaltrials.gov/study/NCT04622319","created_at":"2021-01-19T20:34:44.181Z","updated_at":"2025-02-25T14:59:28.771Z","phase":"Phase 3","brief_title":"A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)","source_id_and_acronym":"NCT04622319 - DESTINY-Breast05","lead_sponsor":"Daiichi Sankyo","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 expression • ER negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 expression • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1600","initiation":"Initiation: 12/04/2020","start_date":" 12/04/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2024-10-09"},{"id":"677800b2-65d4-4839-8d33-a8d6a268ca72","acronym":"STOP-HER2","url":"https://clinicaltrials.gov/study/NCT05721248","created_at":"2023-02-09T15:00:23.584Z","updated_at":"2025-02-25T13:54:55.452Z","phase":"Phase 2","brief_title":"STOP-HER2: Stopping Trastuzumab in HER2+ MBC","source_id_and_acronym":"NCT05721248 - STOP-HER2","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ER negative • HER-2 negative + ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ER negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 04/19/2023","start_date":" 04/19/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2036","study_completion_date":" 02/01/2036","last_update_posted":"2024-09-30"},{"id":"e073adbc-974d-423b-b408-1f0614b44b3b","acronym":"TBCRC 056","url":"https://clinicaltrials.gov/study/NCT04584255","created_at":"2021-01-18T21:52:19.886Z","updated_at":"2025-02-25T13:19:39.281Z","phase":"Phase 2","brief_title":"Niraparib + Dostarlimab in BRCA Mutated Breast Cancer","source_id_and_acronym":"NCT04584255 - TBCRC 056","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • PALB2 mutation • PGR positive","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • PALB2 mutation • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 12/18/2020","start_date":" 12/18/2020","primary_txt":" Primary completion: 07/17/2025","primary_completion_date":" 07/17/2025","study_txt":" Completion: 07/17/2029","study_completion_date":" 07/17/2029","last_update_posted":"2024-09-19"},{"id":"bb271bac-dede-4c19-a4a6-4adacccfde0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03546686","created_at":"2021-01-18T17:27:42.205Z","updated_at":"2025-02-25T14:27:03.665Z","phase":"Phase 2","brief_title":"Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women with Triple-negative Breast Cancer","source_id_and_acronym":"NCT03546686","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 11/12/2019","start_date":" 11/12/2019","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-09-13"},{"id":"8b40b8c5-f34a-4144-9db3-f4f7a7d1b177","acronym":"","url":"https://clinicaltrials.gov/study/NCT01471106","created_at":"2021-01-18T06:07:51.037Z","updated_at":"2025-02-25T14:33:09.458Z","phase":"Phase 2","brief_title":"Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer","source_id_and_acronym":"NCT01471106","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER","pipe":" | ","alterations":" ER negative","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 01/21/2014","start_date":" 01/21/2014","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 05/30/2024","study_completion_date":" 05/30/2024","last_update_posted":"2024-07-10"}]